NMN in Japan

Regulatory status is time-sensitive. This page reflects the Japanese regulatory record as understood on the last-reviewed date below and should be independently verified before any commercial decision. It is educational information, not legal advice.

Why Japan looks different from the US and EU

Japan's system for classifying a substance as "food" versus "drug" (食薬区分, shokuyaku-kubun) is administered by the Ministry of Health, Labour and Welfare (MHLW) through reference lists distinguishing ingredients treated as exclusively pharmaceutical from those not treated as pharmaceutical unless a medicinal claim is made for them. This is a different legal mechanism from the EU's novel food premarket authorization or the US dietary supplement/NDI framework, and the three should not be read as equivalent processes with equivalent evidentiary bars.

What this hub directly verified

This hub directly confirmed, from Japan's Consumer Affairs Agency's own official page, how the Foods with Function Claims (機能性表示食品) system actually works: it is a business self-certification system, not a government approval process — a company submits safety and functionality documentation to the Consumer Affairs Agency Commissioner before selling, but "the state does not conduct examinations" the way it does for a separate, more restrictive category (Foods for Specified Health Uses). Submitted content is published on a public searchable database so consumers can review it directly.[1] This confirms, as a matter of how the Japanese system itself works, that any product registered under this system carries the weight of the company's own submitted evidence, not a government safety or efficacy determination.

What this hub attempted but could not directly verify

This hub attempted a second, more thorough round of primary-source verification specifically for NMN's own entries in Japanese government systems: MHLW's non-drug ingredient lists (via mhlw.go.jp), the Consumer Affairs Agency's Foods with Function Claims notification search database (fld.caa.go.jp), and Japan's Food Safety Commission's own publications. The MHLW list documents are large, periodically-reissued PDFs that could not be parsed for a specific NMN entry during this review; the Consumer Affairs Agency's search database is a JavaScript-driven search tool that could not be queried by this hub's automated tools; and no specific Food Safety Commission publication on NMN could be located directly. A Japanese-government-affiliated reference database (the National Institutes of Biomedical Innovation's health-food safety/efficacy information site) was also checked directly and returned an entry for NMN with its regulatory-classification fields unpopulated — which does not confirm classification either way.

For these specific items, this hub is not able to state NMN's non-drug list classification or any specific Foods with Function Claims registration as independently verified fact: primary-source verification insufficient. Multiple independent regulatory-tracking and industry sources report that NMN was added to a non-drug list around 2020 and that NMN-containing products have since been registered under the Foods with Function Claims system, but this hub could not confirm either claim against the primary Japanese government record during this review.

What this does not establish

None of the above establishes that NMN has been evaluated or approved in Japan for any specific health claim, nor that every (or any specific) NMN product sold in Japan has completed the Foods with Function Claims self-certification process. "Available as a food ingredient in Japan" and "government-endorsed for a specific health benefit" are different claims; this hub does not conflate them, and for now cannot confirm the first claim to its own verification standard either.

Related reading

For the comparative picture across jurisdictions, see NMN Regulatory Status Around the World. For the structured evidence review behind this hub generally, see Research Methodology. For the underlying human clinical evidence — separate from Japan's ingredient-classification question — see NMN Human Clinical Trials.